Esperion Therapeutics, Inc. — Investor Relations & Filings
Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines to reduce cardiovascular risk. The company specializes in once-daily, oral therapies for patients with elevated low-density lipoprotein cholesterol (LDL-C). Its portfolio is centered around adenosine triphosphate-citrate lyase (ACLY) inhibitors, a unique mechanism of action for which it brought the first treatment to market. Key products include NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe), which are approved in the U.S. and Europe. Esperion collaborates with commercial partners to facilitate global access to its medicines while its scientific team investigates new therapeutic opportunities through its pipeline.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K | 2026-06-01 | English | |
| 10-Q - Esperion Therapeutics, Inc. (0001434868) (Filer) | 2026-05-08 | English | |
| 4 - Esperion Therapeutics, Inc. (0001434868) (Issuer) | 2026-03-18 | English | |
| 4 - Esperion Therapeutics, Inc. (0001434868) (Issuer) | 2026-03-18 | English | |
| 4 - Esperion Therapeutics, Inc. (0001434868) (Issuer) | 2026-03-18 | English | |
| 144 - Esperion Therapeutics, Inc. (0001434868) (Subject) | 2026-03-17 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
11 filings
| |||||
| 47923358 | 8-K | 2026-06-01 | English | ||
| 44402054 | 10-Q - Esperion Therapeutics, Inc. (0001434868) (Filer) | 2026-05-08 | English | ||
| 32979258 | 4 - Esperion Therapeutics, Inc. (0001434868) (Issuer) | 2026-03-18 | English | ||
| 32979251 | 4 - Esperion Therapeutics, Inc. (0001434868) (Issuer) | 2026-03-18 | English | ||
| 32979254 | 4 - Esperion Therapeutics, Inc. (0001434868) (Issuer) | 2026-03-18 | English | ||
| 32966978 | 144 - Esperion Therapeutics, Inc. (0001434868) (Subject) | 2026-03-17 | English | ||
| 32966969 | 144 - Esperion Therapeutics, Inc. (0001434868) (Subject) | 2026-03-17 | English | ||
| 32966943 | 144 - Esperion Therapeutics, Inc. (0001434868) (Subject) | 2026-03-17 | English | ||
| 32891844 | 8-K - ESPERION THERAPEUTICS, INC. (0001434868) (Filer) | 2026-03-03 | English | ||
| 29771877 | 4 Filing | 2026-01-21 | English | ||
| 29771890 | 8-K Filing | 2026-01-12 | English | ||
|
2025
4 filings
| |||||
| 12218748 | FORM 4 | 2025-12-18 | English | ||
| 12218750 | FORM 4 | 2025-12-18 | English | ||
| 12218749 | FORM 4 | 2025-12-18 | English | ||
| 12218751 | Regulatory Filings 2025 | 2025-12-17 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Abbott Laboratories (Pakistan) Limited
Manufactures and markets diverse healthcare products: pharm…
|
ABOT | PK | Manufacturing |
|
AbbVie Inc.
A research-based biopharmaceutical company developing and m…
|
ABBV | US | Manufacturing |
|
AbCellera Biologics Inc.
Discovers and develops antibody-based therapeutics using a …
|
ABCL | CA | Manufacturing |
|
AbClon Inc.
Develops antibody-based therapeutics using CAR-T, NEST, and…
|
174900 | KR | Manufacturing |
|
ABEONA THERAPEUTICS INC.
A clinical-stage biopharma developing cell and gene therapi…
|
ABEO | US | Manufacturing |
|
ABINGDON HEALTH PLC
A CDMO specializing in lateral flow assays, offering develo…
|
ABDX | GB | Manufacturing |
|
ABIONYX Pharma
Develops biotherapies and drug delivery vectors using apoli…
|
ABNX | FR | Manufacturing |
|
ABIVAX
Clinical-stage biotech developing therapeutics for chronic …
|
ABVX | FR | Manufacturing |
|
Abivax S.A.
Clinical-stage biotech developing miRNA therapeutics for in…
|
ABVX | US | Manufacturing |
|
ABL Diagnostics
Develops molecular diagnostic solutions for managing infect…
|
ABLD | FR | Manufacturing |
Esperion Therapeutics, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/32771/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=32771 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=32771 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=32771 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 32771}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Esperion Therapeutics, Inc. (id: 32771)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.